Welcome to our dedicated page for Bio-Techne SEC filings (Ticker: TECH), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Bio-Techne Corporation filings document the formal disclosure record for a Minnesota life sciences company that sells reagents, analytical instruments and precision diagnostics. Recent Form 8-K reports furnish quarterly and annual operating results, financial condition updates and cash dividend announcements, with exhibits containing the related earnings and dividend releases.
Governance filings include definitive proxy materials and annual meeting vote results covering board size and director elections. Other current reports disclose executive leadership changes and employment arrangements for segment management, tying corporate governance disclosures to Bio-Techne's diagnostics, spatial biology and analytical solutions operations.
Bio-Techne Corp (TECH) reported an insider equity transaction by a director. On 10/30/2025, the reporting person acquired 1,640 shares of common stock at $0 and received a grant of stock options for 3,777 shares at an exercise price of $60.96, expiring on 10/30/2035.
After these transactions, the director directly beneficially owns 8,775 shares of common stock. The option grant vests on the earlier of the one year anniversary of the grant date (10/30/2025) or the date of Bio-Techne's 2026 annual meeting of shareholders.
Bio‑Techne (TECH) director reported equity changes on 10/30/2025. The filing shows an acquisition of 1,640 shares of Common Stock at $0, bringing direct holdings to 15,411 shares. It also reports a new grant of 3,777 stock options with an exercise price of $60.96 and an expiration on 10/30/2035. According to the note, this option vests on the earlier of the one year anniversary of the grant date (10/30/2025) or the date of Bio‑Techne’s 2026 annual meeting of shareholders.
Bio-Techne (TECH) director John L. Higgins filed a Form 4 reporting equity awards dated 10/30/2025. He acquired 1,640 shares of common stock at $0, bringing his directly held common stock to 66,876 shares after the transaction. He was also granted stock options for 3,777 shares with an exercise price of $60.96, expiring on 10/30/2035. The options vest on the earlier of the one‑year anniversary of the grant date or Bio‑Techne’s 2026 annual meeting of shareholders.
Bio-Techne (TECH) director Alpna Seth reported insider transactions. On 10/30/2025, she acquired 1,640 shares of common stock at $0, bringing her direct holdings to 15,411 shares. She also received a new stock option grant for 3,777 shares at an exercise price of $60.96, expiring on 10/30/2035. The option vests on the earlier of the one-year anniversary of the grant date or the company’s 2026 annual meeting of shareholders.
Bio‑Techne (TECH): Form 4 insider update. Director Amy E. Herr reported an equity grant on 10/30/2025. She acquired 1,640 shares of common stock at $0, bringing direct holdings to 2,680 shares; an additional 2,154 shares are held indirectly by a significant other.
She was also granted a stock option to buy 3,777 shares at $60.96, expiring 10/30/2035; vesting occurs on the earlier of the one‑year anniversary of the grant or the 2026 annual meeting. The filing also lists previously awarded options and restricted stock units held indirectly with specified vesting schedules.
Bio‑Techne (TECH) director Judith V. Klimovsky filed a Form 4 reporting equity awards. On 10/30/2025, she acquired 1,640 shares of common stock at $0, bringing direct holdings to 3,782 shares.
She was also granted a stock option for 3,777 shares at an exercise price of $60.96, expiring 10/30/2035. The option vests on the earlier of the one year anniversary of the grant date (10/30/2025) or the date of Bio‑Techne’s 2026 annual meeting of shareholders. Existing options include 1,610 at $73.46 (exp. 05/01/2034) and 3,511 at $68.37 (exp. 10/24/2034).
Bio‑Techne (TECH) reported an insider equity update. A director acquired 1,640 shares of common stock on 10/30/2025 at a reported price of $0, bringing direct beneficial ownership to 10,987 shares after the transaction.
The filing also lists a new derivative award: 3,777 stock options acquired on 10/30/2025 with an exercise price of $60.96 and an expiration date of 10/30/2035. According to the footnote, the option vests on the earlier of the one‑year anniversary of the grant date (10/30/2025) or the date of Bio‑Techne’s 2026 annual meeting of shareholders.
Bio‑Techne (TECH) director Robert V. Baumgartner reported insider activity. On 10/30/2025, he acquired 1,640 common shares at $0, bringing his directly held shares to 46,503 after the transaction. He was also granted a stock option for 3,777 shares at an exercise price of $60.96, expiring on 10/30/2035. The option vests on the earlier of the one‑year anniversary of the grant date or the company’s 2026 annual meeting of shareholders.
Bio-Techne reshaped its portfolio in fiscal 2025, selling the Exosome Diagnostics business (including the ExoDx Prostate test and related CLIA lab) to Mdxhealth SA and retaining access to the exosome technology for continued kit development. The company introduced over 500 new products in fiscal 2025, including the next-generation Simple Western instrument Leo, ProPak GMP Cytokines, the QuantideX ESR1 exoMutation Kit, and AI-designed proteins, and announced a new EMEA Customer Service Center with a Demonstration Laboratory targeted to launch in summer 2026.
Corporate governance and compensation were updated: the Board maintains separate Chair/CEO roles, independent committees, shareholder rights (proxy access, special meeting rights), and director tenure/retirement policies; compensation changes include adding relative TSR as a metric, a new equity mix (50% performance RSUs, 25% time RSUs, 25% options), and adjusted bonus payout bands. Reported company metrics show market capitalization $11.51B, revenues of $1.15B, adjusted EBITA of $257.4M, and an annualized 3-year TSR of -10% versus peer medians.
Bio-Techne reshaped its portfolio in fiscal 2025, selling the Exosome Diagnostics business (including the ExoDx Prostate test and related CLIA lab) to Mdxhealth SA and retaining access to the exosome technology for continued kit development. The company introduced over 500 new products in fiscal 2025, including the next-generation Simple Western instrument Leo, ProPak GMP Cytokines, the QuantideX ESR1 exoMutation Kit, and AI-designed proteins, and announced a new EMEA Customer Service Center with a Demonstration Laboratory targeted to launch in summer 2026.
Corporate governance and compensation were updated: the Board maintains separate Chair/CEO roles, independent committees, shareholder rights (proxy access, special meeting rights), and director tenure/retirement policies; compensation changes include adding relative TSR as a metric, a new equity mix (50% performance RSUs, 25% time RSUs, 25% options), and adjusted bonus payout bands. Reported company metrics show market capitalization $11.51B, revenues of $1.15B, adjusted EBITA of $257.4M, and an annualized 3-year TSR of -10% versus peer medians.
Roeland Nusse, a director of Bio-Techne Corporation (TECH), reported option exercises and share sales on 08/25/2025. He exercised 17,040 stock options with an exercise price of $21.84 and simultaneously sold 17,040 common shares at a weighted average price of $56.3608, reducing his reported beneficial ownership to 44,559 shares. Table II shows Nusse retains multiple outstanding option grants exercisable into common stock, including 17,040 options exercisable through 10/28/2025 and other option tranches with exercise prices from $25.30 to $128.81. The Form 4 was submitted via attorney-in-fact on 08/27/2025.